Halozyme Therapeutics Company Profile (NASDAQ:HALO)

About Halozyme Therapeutics

Halozyme Therapeutics logoHalozyme Therapeutics, Inc. is a biotechnology company focused on developing and commercializing oncology therapies. The Company operates in research, development and commercialization of enzymes segment. This segment also includes research and development, and bulk rHuPH20 manufacturing activities conducted under its collaborative agreements with third parties, and product sales of Hylenex recombinant. Its development pipeline consists of clinical-stage product candidates in oncology. Its lead oncology program is PEGPH20 (polyethylene glycol (PEG)ylated recombinant human hyaluronidase), a molecular entity being developed for the systemic treatment of tumors, which accumulate HA. It is in Phase II and Phase III clinical testing for PEGPH20 in stage IV pancreatic ductal adenocarcinoma (Studies 109-202 and 109-301); Phase Ib clinical testing in non-small cell lung cancer (Study 107-201), and in Phase Ib clinical testing in non-small cell lung cancer and gastric cancer (Study 107-101).

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Biotechnology
  • Sub-Industry: Biotechnology
  • Exchange: NASDAQ
  • Symbol: HALO
  • CUSIP: 40637H10
Key Metrics:
  • Previous Close: $12.41
  • 50 Day Moving Average: $10.72
  • 200 Day Moving Average: $9.90
  • 52-Week Range: $6.96 - $18.65
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -21.03
  • P/E Growth: 0.00
  • Market Cap: $1.56B
  • Outstanding Shares: 127,958,000
  • Beta: 2.19
Profitability:
  • Net Margins: -44.90%
  • Return on Equity: -234.15%
  • Return on Assets: -28.27%
Debt:
  • Debt-to-Equity Ratio: 20.65%
  • Current Ratio: 7.31%
  • Quick Ratio: 7.04%
Additional Links:
Companies Related to Halozyme Therapeutics:

Analyst Ratings

Consensus Ratings for Halozyme Therapeutics (NASDAQ:HALO) (?)
Ratings Breakdown: 1 Sell Rating, 6 Buy Ratings
Consensus Rating:Buy (Score: 2.71)
Consensus Price Target: $16.13 (29.94% upside)

Analysts' Ratings History for Halozyme Therapeutics (NASDAQ:HALO)
Show:
DateFirmActionRatingPrice TargetDetails
9/16/2016Piper Jaffray Cos.Boost Price TargetOverweight$15.00 -> $18.00View Rating Details
9/8/2016Wells Fargo & Co.Reiterated RatingBuyView Rating Details
6/6/2016Canaccord GenuityReiterated RatingBuy$11.00View Rating Details
5/10/2016Jefferies GroupReiterated RatingSell$6.75View Rating Details
3/9/2016JMP SecuritiesLower Price TargetMarket Outperform$22.00 -> $20.00View Rating Details
2/24/2016Barclays PLCLower Price TargetOverweight$27.00 -> $16.00View Rating Details
11/18/2015Citigroup Inc.Initiated CoverageBuy$25.00View Rating Details
6/22/2015JPMorgan Chase & Co.Boost Price TargetOverweight$20.00 -> $25.00View Rating Details
6/1/2015MLV & Co.Reiterated RatingBuy$20.00View Rating Details
4/20/2015BMO Capital MarketsSet Price TargetBuy$26.00View Rating Details
(Data available from 9/29/2014 forward)

Earnings

Earnings History for Halozyme Therapeutics (NASDAQ:HALO)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
11/7/2016        
8/9/2016Q216($0.27)($0.21)$29.94 million$33.30 millionViewN/AView Earnings Details
5/9/2016Q116($0.20)($0.16)$29.65 million$42.50 millionViewN/AView Earnings Details
2/29/2016Q415($0.08)$0.03$37.06 million$52.20 millionViewListenView Earnings Details
11/9/2015Q315($0.16)($0.19)$24.01 million$20.80 millionViewN/AView Earnings Details
8/10/2015Q215($0.09)$0.02$24.84 million$43.40 millionViewListenView Earnings Details
5/11/2015Q115($0.13)($0.12)$19.40 million$18.70 millionViewListenView Earnings Details
3/2/2015Q414($0.07)($0.04)$25.60 million$30.38 millionViewN/AView Earnings Details
11/10/2014Q314($0.14)($0.16)$16.50 million$14.60 millionViewN/AView Earnings Details
8/11/2014Q214($0.14)($0.13)$13.71 million$18.40 millionViewN/AView Earnings Details
5/12/2014Q114($0.14)($0.22)$13.37 million$12.00 millionViewN/AView Earnings Details
2/27/2014Q413($0.17)($0.19)$21.80 million$12.50 millionViewN/AView Earnings Details
11/8/2013Q313($0.15)($0.17)$14.62 million$16.00 millionViewN/AView Earnings Details
8/7/2013Q2 2013($0.13)($0.13)$11.29 million$14.50 millionViewN/AView Earnings Details
5/8/2013Q1 2013($0.15)($0.17)$7.05 million$11.83 millionViewN/AView Earnings Details
2/25/2013Q4 2012($0.16)($0.04)$7.32 million$21.80 millionViewN/AView Earnings Details
11/8/2012Q312($0.13)($0.18)$6.09 million$5.33 millionViewN/AView Earnings Details
8/6/2012($0.15)($0.13)ViewN/AView Earnings Details
5/7/2012($0.11)$0.14ViewN/AView Earnings Details
3/9/2012($0.16)($0.18)ViewN/AView Earnings Details
11/7/2011($0.03)$0.05ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Halozyme Therapeutics (NASDAQ:HALO)
Current Year EPS Consensus Estimate: $-0.89 EPS
Next Year EPS Consensus Estimate: $-0.59 EPS
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20162($0.20)($0.17)($0.19)
Q2 20161($0.28)($0.28)($0.28)
Q3 20161($0.24)($0.24)($0.24)
Q4 20161($0.30)($0.30)($0.30)
(Data provided by Zacks Investment Research)

Dividends

Dividend History for Halozyme Therapeutics (NASDAQ:HALO)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading History for Halozyme Therapeutics (NASDAQ:HALO)
Insider Ownership Percentage: 16.60%
Institutional Ownership Percentage: 80.41%
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
8/20/2015Laurie StelzerCFOBuy10,000$17.24$172,400.00View SEC Filing  
6/18/2015Kenneth J KelleyDirectorSell20,000$21.00$420,000.00View SEC Filing  
9/16/2014David A RamsayCFOBuy25,000$8.90$222,500.00View SEC Filing  
9/16/2014Helen TorleyCEOBuy50,000$8.92$446,000.00View SEC Filing  
8/19/2014John Stuart PattonDirectorSell75,000$9.96$747,000.00View SEC Filing  
5/15/2014Robert EnglerDirectorSell126,700$7.56$957,852.00View SEC Filing  
9/16/2013John Stuart PattonDirectorSell75,000$9.13$684,750.00View SEC Filing  
8/19/2013H. Michael ShepardVPSell10,000$7.11$71,100.00View SEC Filing  
8/14/2013Kathryn FalbergDirectorBuy100,000$6.82$682,000.00View SEC Filing  
11/29/2012Robert EnglerDirectorBuy15,000$5.57$83,550.00View SEC Filing  
11/14/2012James P ShafferVPBuy20,000$5.22$104,400.00View SEC Filing  
11/13/2012Kathryn E FalbergDirectorBuy50,000$5.21$260,500.00View SEC Filing  
8/27/2012Kenneth J KelleyDirectorBuy20,000$5.70$114,000.00View SEC Filing  
8/13/2012Gregory Ian FrostCEOBuy2,000$5.50$11,000.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Latest Headlines for Halozyme Therapeutics (NASDAQ:HALO)
DateHeadline
mysmartrend.com logoHalozyme Therapeutics Up 19.6% Since SmarTrend Uptrend Call (HALO) (NASDAQ:HALO)
www.mysmartrend.com - September 29 at 10:26 AM
News IconActive biotech company shares in the news: Halozyme Therapeutics, Inc. (NASDAQ:HALO), Incyte Corporation ... - The Voice Registrar (NASDAQ:HALO)
voiceregistrar.com - September 28 at 5:12 PM
News IconBiotech Stocks Worth a Closer Look: Halozyme Therapeutics, Inc. (NASDAQ:HALO), BioMarin Pharmaceutical Inc ... - The Voice Registrar (NASDAQ:HALO)
voiceregistrar.com - September 28 at 10:14 AM
News IconHC Stocks Updates! Concordia International Corp (CXRX), Halozyme Therapeutics, Inc. (NASDAQ:HALO) - share market updates (press release) (NASDAQ:HALO)
sharemarketupdates.com - September 26 at 5:28 PM
News IconActive biotech company shares in the news: Halozyme Therapeutics, Inc. (NASDAQ:HALO), PTC Therapeutics, Inc ... - The Voice Registrar (NASDAQ:HALO)
voiceregistrar.com - September 26 at 5:28 PM
News IconBiotech Stocks To Put On Your Watch List: Halozyme Therapeutics, Inc. (NASDAQ:HALO), Spectrum Pharmaceuticals ... - The Voice Registrar (NASDAQ:HALO)
voiceregistrar.com - September 23 at 10:20 AM
News IconBiotech stocks for your portfolio: Halozyme Therapeutics, Inc. (HALO ... - The Independent Republic (NASDAQ:HALO)
theindependentrepublic.com - September 22 at 8:27 AM
News IconTrading the Biotech News: Threshold Pharmaceuticals Inc. (NASDAQ:THLD), Halozyme Therapeutics, Inc. (NASDAQ ... - The Voice Registrar (NASDAQ:HALO)
voiceregistrar.com - September 22 at 8:27 AM
mysmartrend.com logoUptrend Call Working As Halozyme Therapeutics Stock Rises 15.8% (HALO) (NASDAQ:HALO)
www.mysmartrend.com - September 21 at 3:35 PM
investopedia.com logoHow Halozyme Uses Enzymes to Deliver Drugs (HALO) (NASDAQ:HALO)
www.investopedia.com - September 19 at 5:27 PM
News IconHC Stocks Watchful! Galena Biopharma Inc (GALE), Halozyme ... - share market updates (press release) (NASDAQ:HALO)
sharemarketupdates.com - September 19 at 9:56 AM
News IconTime To Put On The Watch List? - Halozyme Therapeutics, Inc. (NASDAQ:HALO), Spectrum Pharmaceuticals, Inc ... - The Voice Registrar (NASDAQ:HALO)
voiceregistrar.com - September 16 at 5:13 PM
thestreet.com logoOne Reason Why Halozyme Therapeutics (HALO) Stock Is Climbing Today (NASDAQ:HALO)
www.thestreet.com - September 16 at 5:13 PM
News IconActive Biotech Stock News: Spectrum Pharmaceuticals, Inc. (SPPI), Halozyme Therapeutics, Inc. (HALO) - The Independent Republic (NASDAQ:HALO)
theindependentrepublic.com - September 16 at 9:15 AM
News IconNew Market Research Report: Halozyme Therapeutics, Inc. (NASDAQ:HALO)
reports.pr-inside.com - September 14 at 5:28 PM
News IconNews review of 2 biotech stocks: Achillion Pharmaceuticals, Inc ... - The Voice Registrar (NASDAQ:HALO)
voiceregistrar.com - September 13 at 10:09 AM
News IconHC Stocks in Top Row= Halozyme Therapeutics, Inc. (HALO), Edwards Lifesciences Corp (NYSE:EW) - share market updates (press release) (NASDAQ:HALO)
sharemarketupdates.com - September 12 at 10:08 AM
investornewswire.com logoWill Halozyme Therapeutics, Inc. (NASDAQ:HALO) Surprise Analysts? - Investor Newswire (NASDAQ:HALO)
www.investornewswire.com - September 11 at 4:58 PM
prnewswire.com logoHalozyme Therapeutics To Present At The Bank Of America Merrill Lynch 2016 Global Health Care Conference - PR Newswire (press release) (NASDAQ:HALO)
www.prnewswire.com - September 10 at 9:51 AM
News IconBiotech Stocks Worth a Closer Look: Halozyme Therapeutics, Inc. (NASDAQ:HALO), Clovis Oncology, Inc. (NASDAQ ... - The Voice Registrar (NASDAQ:HALO)
voiceregistrar.com - September 10 at 9:51 AM
4-traders.com logoHalozyme Therapeutics : To Present At Upcoming Healthcare Conferences (NASDAQ:HALO)
www.4-traders.com - September 9 at 5:10 PM
capitalcube.com logoETF’s with exposure to Halozyme Therapeutics, Inc. : September 9, 2016 (NASDAQ:HALO)
www.capitalcube.com - September 9 at 5:10 PM
prnewswire.com logoHalozyme Therapeutics To Present At The Bank Of America Merrill Lynch 2016 ... (NASDAQ:HALO)
www.prnewswire.com - September 8 at 5:16 PM
prnewswire.com logoHalozyme Therapeutics To Present At The Bank Of America Merrill Lynch 2016 ... (NASDAQ:HALO)
www.prnewswire.com - September 8 at 5:16 PM
finance.yahoo.com logoHalozyme Therapeutics To Present At The Bank Of America Merrill Lynch 2016 Global Health Care Conference (NASDAQ:HALO)
finance.yahoo.com - September 8 at 5:16 PM
finance.yahoo.com logoHalozyme Therapeutics To Present At The Bank Of America Merrill Lynch 2016 Global Health Care Conference (NASDAQ:HALO)
finance.yahoo.com - September 8 at 5:16 PM
News IconNews review of 2 biotech stocks: ZIOPHARM Oncology, Inc ... - The Voice Registrar (NASDAQ:HALO)
voiceregistrar.com - September 6 at 5:24 PM
News IconHalozyme Therapeutics Names Gergen COO (NASDAQ:HALO)
sdbj.com - September 3 at 9:57 AM
News IconUpcoming Earnings Report: Halozyme Therapeutics, Inc. (NASDAQ:HALO) - The Voice Registrar (NASDAQ:HALO)
voiceregistrar.com - September 2 at 5:17 PM
smarteranalyst.com logoStock Update (NASDAQ:HALO): Halozyme Therapeutics, Inc. Appoints Mark J. Gergen As Chief Operating Officer - Smarter Analyst (NASDAQ:HALO)
www.smarteranalyst.com - September 2 at 10:14 AM
streetinsider.com logoHalozyme Therapeutics (HALO) Appoints New COO (NASDAQ:HALO)
www.streetinsider.com - September 1 at 5:17 PM
smarteranalyst.com logoStock Update (NASDAQ:HALO): Halozyme Therapeutics, Inc. Appoints Mark J. Gergen As Chief Operating Officer (NASDAQ:HALO)
www.smarteranalyst.com - September 1 at 5:17 PM
finance.yahoo.com logo9:01 am Halozyme Therapeutics names Mark Gergen as COO (NASDAQ:HALO)
finance.yahoo.com - September 1 at 5:17 PM
publicnow.com logoHalozyme Names Mark J. Gergen As Chief Operating Officer (NASDAQ:HALO)
www.publicnow.com - September 1 at 5:17 PM
biz.yahoo.com logoHALOZYME THERAPEUTICS INC Files SEC form 8-K, Change in Directors or Principal Officers, Financial Statements and Exh (NASDAQ:HALO)
biz.yahoo.com - September 1 at 5:17 PM
News IconShares Slipping Lower Over the Past Month: Halozyme Therapeutics, Inc. (NASDAQ:HALO) - Post News (NASDAQ:HALO)
www.kentuckypostnews.com - September 1 at 8:18 AM
finance.yahoo.com logoHalozyme Therapeutics To Present At Upcoming Healthcare Conferences (NASDAQ:HALO)
finance.yahoo.com - September 1 at 8:18 AM
News IconActive biotech company shares in the news: Halozyme Therapeutics, Inc. (NASDAQ:HALO), BioMarin Pharmaceutical ... - The Voice Registrar (NASDAQ:HALO)
voiceregistrar.com - August 29 at 5:15 PM
capitalcube.com logoETF’s with exposure to Halozyme Therapeutics, Inc. : August 29, 2016 (NASDAQ:HALO)
www.capitalcube.com - August 29 at 5:15 PM
News IconRatings & Crowd Appeal on Halozyme Therapeutics, Inc. (NASDAQ:HALO) - Post News (NASDAQ:HALO)
www.kentuckypostnews.com - August 23 at 5:31 PM
prnewswire.com logoResearch Report Coverage on Biotech Stocks -- Halozyme Therapeutics, Achillion Pharma, Aegerion Pharma and ... - PR Newswire (press release) (NASDAQ:HALO)
www.prnewswire.com - August 23 at 5:31 PM
News IconResearch Report Coverage on Biotech Stocks -- Halozyme Therapeutics, Achillion Pharma, Aegerion Pharma and Chimerix (NASDAQ:HALO)
www.kswo.com - August 23 at 9:45 AM
News IconThe Key Numbers To Watch From Halozyme Therapeutics, Inc. (NASDAQ:HALO)'s Earnings - The Voice Registrar (NASDAQ:HALO)
voiceregistrar.com - August 19 at 8:18 AM
finance.yahoo.com logoHALOZYME THERAPEUTICS INC Financials (NASDAQ:HALO)
finance.yahoo.com - August 18 at 5:23 PM
News IconTrading the Biotech News: Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN), Halozyme Therapeutics, Inc. (NASDAQ ... - The Voice Registrar (NASDAQ:HALO)
voiceregistrar.com - August 18 at 8:22 AM
capitalcube.com logoETF’s with exposure to Halozyme Therapeutics, Inc. : August 15, 2016 (NASDAQ:HALO)
www.capitalcube.com - August 15 at 5:34 PM
News IconHalozyme Therapeutics Increases Estimate for Yearly Net Revenue (NASDAQ:HALO)
sdbj.com - August 14 at 5:14 PM
News IconHalozyme Increases Estimate for Yearly Net Revenue (NASDAQ:HALO)
sdbj.com - August 12 at 5:26 PM
capitalcube.com logoHalozyme Therapeutics, Inc. :HALO-US: Earnings Analysis: Q2, 2016 By the Numbers : August 12, 2016 (NASDAQ:HALO)
www.capitalcube.com - August 12 at 5:26 PM
News Icon8-K: HALOZYME THERAPEUTICS INC (NASDAQ:HALO)
www.traderplanet.com - August 10 at 5:40 PM

Social

Halozyme Therapeutics (NASDAQ:HALO) Chart for Thursday, September, 29, 2016


Last Updated on 9/29/2016 by MarketBeat.com Staff